

that, overall, these 2 regimens allows similar reduced TRM and high one-year OS for hematological malignancies and could be selected for further phase III comparison with myeloablative regimen. Further details of sub-group analysis (disease status; acute leukemia, NHL and MM) will be presented in order to assess this conclusion in specific situations with a median study follow-up of 44 [6–78] months.

276

APPLICATION OF SECOND GENERATION TYROSINE KINASE INHIBITORS IN BCR-ABL POSITIVE MALIGNANCIES IN THE POST-TRANSPLANT PERIOD

Klyuchnikov, E.^{1,2}, Osanmaz, O.¹, Schafhausen, P.³, Asenova, S.¹, Zabelina, T.¹, Ayuk, F.¹, Bruemmendorf, T.³, Zander, A.R.¹, Kroeger, N.¹, Bacher, U.¹ ¹University Cancer Center Hamburg (UCCH), Hamburg, Germany; ²St. Petersburg State Pavlov's Medical University, St. Petersburg, Russian Federation; ³University Cancer Center Hamburg (UCCH), Hamburg, Germany

Due to the shift of allogeneic stem cell transplantation (SCT) to poor risk cases in chronic myeloid leukemia (CML), therapy of relapse after SCT is highly relevant. In contrast to Imatinib (IM), where application in stem cell recipients was investigated in many studies, studies on 2nd generation tyrosine kinase inhibitors (TKIs) in the post-transplant period are limited. We performed evaluation of 25 stem cell recipients with CML and 13 with Phil positive ALL (Phi⁺ALL). 9 of those pts received 2nd generation TKIs in the post-transplant period (CML blast phase; BP: n = 6; CML accelerated phase; AP: n = 2; Phi⁺ALL; n = 1). There were 5 males and 4 females (median age 54 years). Before allo-SCT, 7 were in hematological remission, 8 pts were MRD positive. 3 pts had Imatinib resistance conferring mutations (T315I, Y253H, L387F). All pts received unrelated SCT after myeloablative/reduced conditioning. Indications for the post-transplant application of dasatinib were as follows: Phi⁺ALL: molecular relapse: n = 1; CML: relapse of BP: n = 2, extramedullary CML relapse with skeletal/cutaneous or central nervous manifestations: n = 4, refractory extramedullary manifestation: n = 1, persisting MRD: n = 1. The median interval between SCT and dasatinib was 7 months (3–19). Before start of dasatinib after SCT, 4 cases had been refractory to imatinib. Starting dose of dasatinib was 2 × 70 mg or 2 × 50 mg. Dose escalation was possible in 3 pts; reduction was necessary in 1 pt. In 1 pt dasatinib was interrupted due to gastrointestinal intolerance/thrombocytopenia. Median treatment duration was 9 months (range 1–17). 3 cases showed response to therapy: 1 pt is in stable major mol. remission, 2 other patients are in partial remission of extramedullary relapse. 1 pt suffers from meningitis leukemica and receives intrathecal cytarabine. Due to refractoriness, the ALL pt was transferred to nilotinib. 4 pts (44%) died after 6, 7, 9, and 33 months from SCT due to progression. Median overall survival after start of dasatinib was 10 months. In conclusion, although the limited sample has to be considered, it seems that dasatinib can be administered with acceptable tolerance in the post-transplant period and is able to stabilize the situation in single cases of extramedullary or hematological relapse after SCT even in advanced disease and in a poor-risk situation. Future prospective studies should further evaluate the best application schedules of 2nd generation TKIs in the post-transplant period.

277

CLINICAL AND COST OUTCOMES OF DOUBLE UMBILICAL CORD BLOOD VERSUS BONE MARROW AND PERIPHERAL BLOOD UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTS

Lopez-Gonzalez, G.¹, LeMaistre, C.F.¹, Bachier, C.¹, Smith, B.², Chan, K.W.¹, Grimley, M.¹, Cain, W.¹, Delgado, E.¹, Kaleel, S.¹, Shaughnessy, P.¹ ¹Texas Transplant Institute, San Antonio, TX; ²Altarum, San Antonio, TX

Umbilical cord blood (UCB) is a viable source of hematopoietic stem cells (HSC) however, because of the risk of nonengraftment with low total nucleated cell counts (TNC) per kg, double UCB (DCB) transplants are used in larger patients (pts). We conducted

a retrospective review of DCB transplants (n = 30) from January 2004 through April 2008 compared to bone marrow (n = 23, 30%) and peripheral blood (n = 54, 70%) unrelated donor (UD) transplants during the same time period. Median age was 21 yrs (range 13–66) for DCB recipients and 45 yrs (range 0.4–67) for UD pts. UD pts were HLA typed at A, B, C, DR, and DQ and matched with donors at 9(10) (21%) and 10(10) (79%) loci [all mismatches at class I alleles]. DCB recipients had HLA matches of 6/6, 5/6, 4/6 and 3/6 as follows: (cord 1/ cord 2): (0.0%/6.7%), (20.0%/30.0%), (76.7%/63.3%), (3.3%/0.0%). The median TNC/kg in DCB pts was 2.03 × 10⁷ (range 7.9 × 10⁶–9.3 × 10⁸). Median day to ANC>500/ul for DCB and UD pts was 23 days (range 6–66) and 15 days (range 7–52), and platelet >20,000/ul was 52 days (range 7–130) and 19 days (range 9–63), respectively. Incidences of acute GVHD ≥2 and chronic GVHD in the UD and DCB pts were 61.0% and 51% vs. 53.3% and 45%, respectively. Median follow-up was 143 days (range 12–847) for the DCB group and 242 days (range 34–1506) for the UD pts. Estimated overall survival (OS) at 1 year was 61% (95% CI: 48% to 71%) for UD pts vs. 55% (95% CI: 34% to 72%) in DCB pts (p = NS). Estimated transplant related mortality (TRM) at 100 days for UD pt was 6.5% (95% CI: 2.8% to 14.9%) and 16.7% (95% CI: 7.3% to 35.5%) (p = 0.09) in DCB pts. All facility transplant related costs were reviewed from the transplant center thru the first year post transplant, excluding pretransplant workup and care not received at the transplant center. The total median costs for DCB transplants were significantly more than the UD costs at D30, D100 and 1yr post transplant by differences of \$42,067, \$50,806, and \$52,297, respectively (p<0.05 for each time interval). The median length of stay for initial hospitalization at start of preparative regimen was 22 days (2–144) in the UD pts and 29 days (6–103) in the DCB pts, and 60% of total median costs occurred by D30 in the DCB group compared to 52% in the UD group. In conclusion, DCB provides a viable option for HSC with comparable clinical outcomes to UD transplants, however DCB transplants are more expensive primarily because of inpatient costs in the first 30 days.

278

BUILDING AN ETHNICALLY DIVERSE CORD BLOOD INVENTORY: A SINGLE INSTITUTION'S INITIATIVE TO INCREASE AFRICAN AMERICAN DONATIONS

Triplett, B.¹, Wofford, J.², Mueckl, K.², Regan, D.², Geiler, V.² ¹SSM Cardinal Glennon Children's Medical Center/Saint Louis University, St. Louis, MO; ²The St. Louis Cord Blood Bank At SSM Cardinal Glennon Children's Medical Center, St. Louis, MO

In 2005, the United States Congress passed the Stem Cell Therapeutic and Research Act. A central component of this legislation was the development of the National Cord Blood Inventory (NCBI). A competitive bidding process was instituted and to date three cohorts of banks have been funded with the charge to collect and store 150,000 new cord blood units. A goal in the development of this new inventory is to increase the number of cord blood units from underrepresented racial and ethnic groups. The St. Louis Cord Blood Bank (SLCBB) began participating in this program in September of 2007. The focus for our bank in achieving the goal of diversification was to establish strategies for recruiting African American donors. Historically, this ethnic group has not widely participated in cord blood donation in the St. Louis area. A pilot study was instituted by the SLCBB at SSM St. Mary's Health Center in October of 2007. This hospital was chosen due to its diverse patient population. We hypothesized that the insertion of a dedicated staff nurse into this facility, to educate and communicate directly with potential donors, would result in a significant increase in donations from African Americans. The results from this study are dramatic. A total of 448 cord blood units were collected during the study period (October 1, 2007 – September 30, 2008) as compared to 54 cord blood units during the previous 12 month period (p = <0.0001). This equates to a 730% increase in African American donations. This pilot study demonstrated that the SLCBB initiative was successful not only in increasing the donation rate among African Americans, but also an awareness of the life-saving benefits of cord blood. While donations have increased at a significant